McDermott advises Ardian Growth in the Acquisition of a Minority Stake in H2 Pharma, a Leading French Pharmaceuticals Company
Ardian Growth announced its acquisition of an equity stake in H2 Pharma, a French company specialized in the development and production of generic drugs. This is Ardian Growth’s first investment in the healthcare sector.
H2 Pharma is a partner of many pharmaceutical laboratories in the manufacture of generic and over-the-counter drugs. With an exceptionally strong position in the non-sterile pharmaceutical liquids segment (mouthwashes, syrups, oral solutions, etc.), H2 Pharma is involved in all stages of a drug’s value chain: from the supply of the active ingredient to the production of the finished product, including development and regulatory aspects.
McDermott Will & Emery assisted ArdianGrowth with a team comprising:
Paris is McDermott’s first location outside the United States. As part of the McDermott Will & Emery international network, the 80 lawyers in the Paris office strive to bring real added value to companies, their managers and public and private institutions through excellent legal support. We regularly receive awards for the quality, consistency and creativity of the solutions we offer. McDermott is listed in the Chambers & Partners Europe and Legal 500 EMEA rankings. McDermott Will & Emery is one of the largest international law firms. It has more than 1,200 lawyers in 20 offices in North America, and Europe. As a truly integrated platform, McDermott enables its various teams around the world to work closely and regularly together.